p53 biology and reactivation for improved therapy in MDS and AML
Abstract Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) originate from preleukemic hematopoietic conditions, such as clonal hematopoiesis of indeterminate potential (CHIP) or clonal cytopenia of undetermined significance (CCUS) and have variable outcomes despite the successful imple...
Saved in:
Main Author: | Joanna E. Zawacka (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2024-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Severe congenital neutropenia, a genetically heterogeneous disease group with an increased risk of AML/MDS
by: Peter Vandenberghe, et al.
Published: (2011) -
Cutaneous Leukemic Infiltrates Successfully Treated With Biomodulatory Therapy in a Rare Case of Therapy-Related High Risk MDS/AML
by: Daniel Heudobler, et al.
Published: (2018) -
What after MDS?
by: Vijay Deshmukh
Published: (2014) -
Chemical Variations on the p53 Reactivation Theme
by: Carlos J. A. Ribeiro, et al.
Published: (2016) -
Why not MDS in dental material sciences?
by: Vijay Deshmukh
Published: (2016)